Itraconazole - Sebela Pharmaceuticals

Drug Profile

Itraconazole - Sebela Pharmaceuticals

Alternative Names: Hyphanox; ONMEL; Sporamelt

Latest Information Update: 23 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Barrier Therapeutics Inc
  • Developer Sebela Pharmaceuticals
  • Class Antifungals; Azoles; Chlorobenzenes; Piperazines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Onychomycosis

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 27 Nov 2012 Merz Pharma acquires itraconazole from Stiefel
  • 30 Apr 2010 Registered for Onychomycosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top